Clinical Trials Logo

Filter by:
NCT ID: NCT06238817 Recruiting - Atopic Dermatitis Clinical Trials

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

TRuE-AD4
Start date: April 26, 2024
Phase: Phase 3
Study type: Interventional

This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.

NCT ID: NCT06237920 Recruiting - Neoplasms Clinical Trials

Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

TURANDORELA
Start date: February 19, 2024
Phase: Phase 2
Study type: Interventional

This is a non-blinded phase 2 trial in Stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab to assess whether bladder preservation after dual immunotherapy would be a viable treatment option for patients responding to treatment

NCT ID: NCT06237712 Enrolling by invitation - CKD Clinical Trials

Explorative Study to Investigate the Acid-base Response to Sodium and Potassium Salts in Patients With Chronic Kidney Disease.

5S
Start date: January 26, 2024
Phase: N/A
Study type: Interventional

With this research the investigators want to study how patients with chronic kidney disease respond to different sodium- and potassium salts. Potassium salts can prevent kidney damage and cardiovascular disease, however patients with chronic kidney disease can responds differently. Extra potassium can increase the amount of potassium in the blood and extra chloride can cause acidosis. With this study the investigators will gain more insight in how patients with chronic kidney disease respond to sodium and potassium salts and which one is more favorable.This information can then be used to guide the application of salt substitutes and dietary adjustments in patients with chronic kidney disease.

NCT ID: NCT06237699 Recruiting - Quality of Life Clinical Trials

Effects of a Digital Diary on the Psychological Well-being of Former ICU Patients.

DIPIC
Start date: May 1, 2023
Phase:
Study type: Observational [Patient Registry]

Previous research on the impact of a diary on mental symptoms of PICS, PICS-F, and quality of life in former ICU patients and their relatives has focused specifically on a paper diary. While there has been research on the experiences of former ICU patients, relatives, and ICU nurses regarding the use of a digital diary, it is not known whether this diary has an impact on the psychological well-being and quality of life of former ICU patients and their relatives. A successful implementation of [the digital diary] enables this research. The aim of this study is, therefore, to provide an initial impression of the health-related effects of a digital diary on former ICU patients and their relatives.

NCT ID: NCT06236334 Recruiting - Pre-diabetes Clinical Trials

ELFI Health (e-Health for Empowerment by Lifestyle, Food Advice and Interaction)

ELFI
Start date: March 25, 2024
Phase: N/A
Study type: Interventional

In the present study the investigators will examine whether people living with prediabetes benefit from an e-health lifestyle intervention of three months.

NCT ID: NCT06235957 Not yet recruiting - Fractures, Bone Clinical Trials

Three Weeks of Cast Immobilisation Versus One Week of Brace Immobilisation in Distal Radius Fractures

DRPIPIII
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Three weeks of cast immobilisation versus one week of brace immobilisation in non- or minimally displaced distal radius fractures in adult patients <50 years of age treated non-operatively.

NCT ID: NCT06235710 Recruiting - Clinical trials for Rheumatoid Arthritis

Prevalence of Musculoskeletal Complaints in Nursing Home Residents

Start date: January 18, 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to investigate the prevalence of joint complaints in nursing home residents with and without dementia. Primary objective: Number of tender or swollen joints. Secondary objectives: 1. Only when it is possible for the nursing home resident to provide us this information: how nursing home residents themselves assess the severity of their joint complaints that day (at that time). If the nursing home resident cannot answer this question (reliably), we use the Pain Assessment Checklist for Seniors with Severe Dementia (PACSLAC-D). 2. Investigate mobility limitations among nursing home residents. 3. To understand whether an accurate (differential) diagnosis for the joint complaints is reported in the electronic files. During the study, a standard physical examination of the musculoskeletal system will performed. Nursing home residents allocated in group 1 (no dementia) also provide an answer on 3 non-incriminating questions (severity of joint complaints, pain in general and general health). Nursing home residents allocated in group 2 (dementia) answer, if possible, 1 non-incriminating question (pain in joints at that moment). These question(s) and the physical examination are also widely used in daily clinical practice. No further incriminating questions or questionnaires will be administered. If the nursing home resident cannot answer this question (reliably), we use the PACSLAC-D.

NCT ID: NCT06233461 Recruiting - Crohn's Disease Clinical Trials

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Start date: March 5, 2024
Phase: Phase 2
Study type: Interventional

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. An endoscopy will be used to check the bowel for inflammation. The participants will be treated with TAK-279 for 52 weeks (1 year). During the study, participants will visit their study clinic 15 times.t

NCT ID: NCT06232889 Recruiting - Clinical trials for Fluorodeoxyglucose F18

Deuterium Metabolic MRI and [18F]FDG PET for Assessment of Treatment Response Following Radioembolization

DEPLETE
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

Radioembolization, also known as Selective Internal Radiation Therapy (SIRT), is a liver-directed therapy for patients suffering from hepatic metastases. As SIRT is a liver-directed treatment, only patients with liver-only or liver-dominant disease are eligible for treatment. FDG-PET/CT is known to outperform conventional anatomical imaging modalities (CT or MRI) for treatment response assessment, also being of prognostic value. Subsequently following SIRT, patients are restaged with FDG-PET/CT. However, optimal timing of restaging following treatment is unknown (most commonly after 1 or 3 months, according to local institutional guidelines). More importantly, intrinsic resolution of FDG-PET/CT limits its utility in patients with small metastases, as image quality is worsened by high background noise, due to physiologic FDG uptake / metabolism in normal liver parenchyma. Additionally, FDG as radiopharmaceutical increases additional radiation burden to patients. This study will investigate the potential of metabolic MRI (7T MRI), non-invasively imaging metabolites using X-nuclei (e.g. 31P MRSI) and more importantly, the application of Deuterium Metabolic Imaging (DMI) with non-radioactive deuterated glucose, as a potential alternative over FDG-PET/CT.

NCT ID: NCT06232109 Recruiting - Clinical trials for Drug Drug Interaction

Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects

Start date: February 22, 2024
Phase: Phase 1
Study type: Interventional

The drug-drug interaction study has been designed to investigate the effect of Fluvoxamine, Itraconazole and Paroxetine on the pharmacokinetics of ASN51